These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 33795526)

  • 1. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
    Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
    Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
    Karlo CA; Di Paolo PL; Chaim J; Hakimi AA; Ostrovnaya I; Russo P; Hricak H; Motzer R; Hsieh JJ; Akin O
    Radiology; 2014 Feb; 270(2):464-71. PubMed ID: 24029645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computed tomography-based radiomics prediction of CTLA4 expression and prognosis in clear cell renal cell carcinoma.
    He H; Jin Z; Dai J; Wang H; Sun J; Xu D
    Cancer Med; 2023 Mar; 12(6):7627-7638. PubMed ID: 36397666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
    Vlachostergios PJ; Papathanassiou M; Anagnostou M; Thodou E; Tamposis I; Mitrakas L; Zachos I; Koukoulis GK; Samara M; Tzortzis V
    F1000Res; 2023; 12():918. PubMed ID: 38933491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
    Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
    Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a CT-based nomogram for preoperative prediction of clear cell renal cell carcinoma grades.
    Zheng Z; Chen Z; Xie Y; Zhong Q; Xie W
    Eur Radiol; 2021 Aug; 31(8):6078-6086. PubMed ID: 33515086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning-based unenhanced CT texture analysis for predicting BAP1 mutation status of clear cell renal cell carcinomas.
    Kocak B; Durmaz ES; Kaya OK; Kilickesmez O
    Acta Radiol; 2020 Jun; 61(6):856-864. PubMed ID: 31635476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status.
    Kocak B; Durmaz ES; Ates E; Ulusan MB
    AJR Am J Roentgenol; 2019 Mar; 212(3):W55-W63. PubMed ID: 30601030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CT-based radiomics nomogram for differentiation of renal angiomyolipoma without visible fat from homogeneous clear cell renal cell carcinoma.
    Nie P; Yang G; Wang Z; Yan L; Miao W; Hao D; Wu J; Zhao Y; Gong A; Cui J; Jia Y; Niu H
    Eur Radiol; 2020 Feb; 30(2):1274-1284. PubMed ID: 31506816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of Clear Cell and Non-clear-cell Renal Cell Carcinoma through CT-based Radiomics Models and Nomogram.
    Cheng D; Abudikeranmu Y; Tuerdi B
    Curr Med Imaging; 2023; 19(9):1005-1017. PubMed ID: 36411581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomics nomogram based on CT radiomics features and clinical factors for prediction of Ki-67 expression and prognosis in clear cell renal cell carcinoma: a two-center study.
    Li B; Zhu J; Wang Y; Xu Y; Gao Z; Shi H; Nie P; Zhang J; Zhuang Y; Wang Z; Yang G
    Cancer Imaging; 2024 Aug; 24(1):103. PubMed ID: 39107799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
    Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics predicts the prognosis of patients with clear cell renal cell carcinoma by reflecting the tumor heterogeneity and microenvironment.
    Wu J; Li J; Huang B; Dong S; Wu L; Shen X; Zheng Z
    Cancer Imaging; 2024 Sep; 24(1):124. PubMed ID: 39285496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.